SML0650

Risedronate sodium

≥97% (HPLC)

• Sinonimo/i: P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt
• Formula empirica (notazione di Hill): C₇H₁₀NO₇P₂ · Na
• Numero CAS: 115436-72-1
• Peso molecolare: 305.09
• UNSPSC Code: 41106300
• NACRES: NA.77
• Assay: ≥97% (HPLC)
• Form: powder

Proprietà

• Quality Segment: 100
• assay: ≥97% (HPLC)
• form: powder
• color: white to beige
• solubility: H₂O: 5 mg/mL, clear (warmed)
• storage temp.: room temp
• SMILES string: [Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1
• InChI: 1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1
• InChI key: DRFDPXKCEWYIAW-UHFFFAOYSA-M

Descrizione

Biochem/physiol Actions

Risedronate sodium is a bisphosphonate bone resorption inhibitor.

Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.

Informazioni sulla sicurezza

• Pittogrammi: GHS07
• Parola di avvertenza: Warning
• Codici di pericolo: H302 + H312 + H332
• Avvertenze di sicurezza: P261 - P264 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral
• Classe di stoccaggio: 11 - Combustible Solids
• Che succede?: WGK 3
• Punto di infiammabilità (°F): Not applicable
• Punto di infiammabilità (°C): Not applicable